Literature DB >> 30158299

Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Michael D Parkins1,2, Ranjani Somayaji3,2, Valerie J Waters4,5.   

Abstract

Chronic lower airway infection with Pseudomonas aeruginosa is a major contributor to morbidity and mortality in individuals suffering from the genetic disease cystic fibrosis (CF). Whereas it was long presumed that each patient independently acquired unique strains of P. aeruginosa present in their living environment, multiple studies have since demonstrated that shared strains of P. aeruginosa exist among individuals with CF. Many of these shared strains, often referred to as clonal or epidemic strains, can be transmitted from one CF individual to another, potentially reaching epidemic status. Numerous epidemic P. aeruginosa strains have been described from different parts of the world and are often associated with an antibiotic-resistant phenotype. Importantly, infection with these strains often portends a worse prognosis than for infection with nonclonal strains, including an increased pulmonary exacerbation rate, exaggerated lung function decline, and progression to end-stage lung disease. This review describes the global epidemiology of clonal P. aeruginosa strains in CF and summarizes the current literature regarding the underlying biology and clinical impact of globally important CF clones. Mechanisms associated with patient-to-patient transmission are discussed, and best-evidence practices to prevent infections are highlighted. Preventing new infections with epidemic P. aeruginosa strains is of paramount importance in mitigating CF disease progression.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Liverpool epidemic strain; Pseudomonas aeruginosa; bronchiectasis; clone C; cystic fibrosis; epidemic strains; genotyping; infection control; shared strains; strain typing; transmissible strain

Mesh:

Year:  2018        PMID: 30158299      PMCID: PMC6148191          DOI: 10.1128/CMR.00019-18

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  283 in total

1.  Update in cystic fibrosis 2008.

Authors:  Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2009-03-15       Impact factor: 21.405

2.  Phages in nature.

Authors:  Martha Rj Clokie; Andrew D Millard; Andrey V Letarov; Shaun Heaphy
Journal:  Bacteriophage       Date:  2011-01

3.  Isolation of an IHF-deficient mutant of a Pseudomonas aeruginosa mucoid isolate and evaluation of the role of IHF in algD gene expression.

Authors:  I Delic-Attree; B Toussaint; A Froger; J C Willison; P M Vignais
Journal:  Microbiology       Date:  1996-10       Impact factor: 2.777

4.  Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients.

Authors:  G Fluge; B Ojeniyi; N Høiby; A Digranes; O Ciofu; E Hunstad; O C Haanaes; O T Storrøsten
Journal:  Clin Microbiol Infect       Date:  2001-05       Impact factor: 8.067

5.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

6.  Cross-sectional and longitudinal multilocus sequence typing of pseudomonas aeruginosa in cystic fibrosis sputum samples.

Authors:  David J Waine; David Honeybourne; E Grace Smith; Joanna L Whitehouse; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

7.  PCR-based detection of a cystic fibrosis epidemic strain of Pseudomonas Aeruginosa.

Authors:  Stavroula Panagea; Craig Winstanley; Yasmin N Parsons; Martin J Walshaw; Martin J Ledson; C Anthony Hart
Journal:  Mol Diagn       Date:  2003

8.  Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis.

Authors:  K J Psoter; A J DE Roos; J Wakefield; J D Mayer; M Bryan; M Rosenfeld
Journal:  Epidemiol Infect       Date:  2015-10-09       Impact factor: 2.451

9.  Genotypic and phenotypic relatedness of Pseudomonas aeruginosa isolates among the major cystic fibrosis patient cohort in Italy.

Authors:  Cristina Cigana; Paola Melotti; Rossella Baldan; Elisa Pedretti; Emily Pintani; Patrizia Iansa; Ida De Fino; Flavio Favari; Gabriella Bergamini; Gloria Tridello; Daniela M Cirillo; Baroukh M Assael; Alessandra Bragonzi
Journal:  BMC Microbiol       Date:  2016-07-11       Impact factor: 3.605

Review 10.  Medical and microbiological problems arising from airborne infection in hospitals.

Authors:  K P Schaal
Journal:  J Hosp Infect       Date:  1991-06       Impact factor: 3.926

View more
  54 in total

1.  The Natural Product Elegaphenone Potentiates Antibiotic Effects against Pseudomonas aeruginosa.

Authors:  Weining Zhao; Ashley R Cross; Caillan Crowe-McAuliffe; Angela Weigert-Munoz; Erika E Csatary; Amy E Solinski; Joanna Krysiak; Joanna B Goldberg; Daniel N Wilson; Eva Medina; William M Wuest; Stephan A Sieber
Journal:  Angew Chem Int Ed Engl       Date:  2019-05-16       Impact factor: 15.336

2.  Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Authors:  Miquel B Ekkelenkamp; Rafael Cantón; María Díez-Aguilar; Michael M Tunney; Deirdre F Gilpin; Francesca Bernardini; Glenn E Dale; J Stuart Elborn; Jumamurat R Bayjanov; Ad Fluit
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  The Pseudomonas aeruginosa Population among Cystic Fibrosis Patients in Quebec, Canada: a Disease Hot Spot without Known Epidemic Isolates.

Authors:  Julie Jeukens; Luca Freschi; Irena Kukavica-Ibrulj; Jean-Guillaume Emond-Rheault; Christian Allard; Jean Barbeau; André Cantin; Steve J Charette; Eric Déziel; François Malouin; Julie Milot; Dao Nguyen; Clara Popa; Brian Boyle; Roger C Levesque
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

4.  The ThiL enzyme is a valid antibacterial target essential for both thiamine biosynthesis and salvage pathways in Pseudomonas aeruginosa.

Authors:  Hyung Jun Kim; Hyunjung Lee; Yunmi Lee; Inhee Choi; Yoonae Ko; Sangchul Lee; Soojin Jang
Journal:  J Biol Chem       Date:  2020-05-13       Impact factor: 5.157

5.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

6.  RegulomePA: a database of transcriptional regulatory interactions in Pseudomonas aeruginosa PAO1.

Authors:  Edgardo Galán-Vásquez; Beatriz Carely Luna-Olivera; Marcelino Ramírez-Ibáñez; Agustino Martínez-Antonio
Journal:  Database (Oxford)       Date:  2020-12-01       Impact factor: 3.451

Review 7.  Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

Authors:  N Mayer-Hamblett; D R VanDevanter
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

Review 8.  Harnessing bacterial interactions to manage infections: a review on the opportunistic pathogen Pseudomonas aeruginosa as a case example.

Authors:  Chiara Rezzoagli; Elisa T Granato; Rolf Kümmerli
Journal:  J Med Microbiol       Date:  2020-01-21       Impact factor: 2.472

9.  Polyclonality, Shared Strains, and Convergent Evolution in Chronic Cystic Fibrosis Staphylococcus aureus Airway Infection.

Authors:  Dustin R Long; Daniel J Wolter; Michael Lee; Mimi Precit; Kathryn McLean; Elizabeth Holmes; Kelsi Penewit; Adam Waalkes; Lucas R Hoffman; Stephen J Salipante
Journal:  Am J Respir Crit Care Med       Date:  2021-05-01       Impact factor: 21.405

10.  Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.

Authors:  Yu Lin; Diana Quan; Rachel Yoon Kyung Chang; Michael Y T Chow; Yuncheng Wang; Mengyu Li; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2020-11-27       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.